-
SAB Biotherapeutics Doses First Patient with SAB-185 for the Treatment of COVID-19 in NIH’s ACTIV-2 Phase 2/3 Clinical Trial
Part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2) master protocol Trials are funded, sponsored and conducted by…
-
SAB Biotherapeutics Strengthens Senior Management Team with Appointment of Kipp Erickson, PhD as Chief Operating Officer
Company promotes SAB team members in key areas April 13, 2021 10:10AM CENTRAL DAYLIGHT TIME SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics…
-
SAB Biotherapeutics to Present at Upcoming March Investor Conferences
March 4, 2021 03:30PM CENTRAL STANDARD TIME SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company…
-
SAB Biotherapeutics Announces New Appointments to its Board of Directors
December 16, 2020 06:00AM CENTRAL STANDARD TIME SIOUX, FALLS, SD--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a…
-
SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
November 30, 2020 07:45 AM EASTERN STANDARD TIME SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical…
-
SAB Biotherapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of SAB-185 For The Treatment Of COVID-19
Phase 1b clinical trial will evaluate the safety and pharmacological activity of SAB-185 in COVID-19 patients Second study initiated this month testing…
-
SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-185 For The Treatment And Prevention Of COVID-19
First participant dosed in Phase 1 study of SAB-185 for COVID-19 in healthy volunteers Phase 1b clinical trial evaluating the safety and pharmacological…
-
SAB Biotherapeutics Awarded $35.6M From U.S. Department Of Defense For COVID-19 And Scaling Rapid Response Antibody Program
Funds clinical development and manufacturing of SAB-185, a therapeutic candidate for COVID-19, as well as increased production capacity for rapid…
-
SAB Biotherapeutics Announces First Participant Dosed In Phase 1 Clinical Trial Of SAB-176 For Seasonal Influenza
July 30, 2020 08:48 AM Eastern Daylight Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company…
-
SAB Biotherapeutics Closes Series B Funding
July 17, 2020 12:18 PM Eastern Daylight Time SIOUX FALLS, S.D.(BUSINESS WIRE)SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company…
-
Cows Help With COVID-19 Treatment, No Bull
June 17, 2020 5:00 AM ET | Joe Palca It turns out, cows may play an important role in responding to the COVID-19 pandemic. SAB Biotherapeutics is in the…
-
Human Trials Expected To Start Next Month For Covid-19 Treatment Derived From Cows’ Blood
By Elizabeth Cohen, CNN Senior Medical Correspondent | Updated 10:41 PM ET, Tue June 16, 2020 (CNN) A South Dakota company expects to start human trials…